WASHINGTON, April 4, 2018 /PRNewswire/ --
The Society of Interventional Oncology (SIO), an international
organisation working to nurture and support interventional oncology
worldwide, and BTG plc (LSE: BTG), a global healthcare company
focused on Interventional Medicine, announce their 2018
Interventional Oncology/Immuno-Oncology research grant
recipients.
The investigators and project proposals that have been awarded
grants are:
Rony Avritscher
University of Texas MD Anderson Cancer Center
Strategies to Modulate Liver Tumor Immune Microenvironment after
Catheter-based Drug Delivery
Terence Gade, University of Pennsylvania
University of Pennsylvania
Characterization of the Immunobiologic Response Following
Transarterial Chemoembolization of HCC
Samdeep Mouli
Northwestern
University
Y90 Radioembolization Combined with
Immune Checkpoint Blockade in an Animal Model of Hepatocellular
Isabel Newton
University of California, San
Diego
Effects of Cryoablation on Hepatocellular Carcinoma Cancer Stem
Cells and the Immune Response
Paul Thevenot
Ochsner Health System
Tumor-Induced Tolerance in Driving Embolization Resistance and
Waitlist/Transplant Outcomes
"We are very pleased that with the continued generosity of BTG,
SIO has been able to fund a second round of highly meritorious,
cutting-edge research that combines the strengths of interventional
oncology and immuno-oncology-two disciplines that hold great
promise for improving cancer therapy," stated S. Nahum Goldberg, MD, SIO
Interventional/Immuno-oncology Working Group Chair, and Vice-Chair
for Research and Head of the Interventional Oncology Unit, Hadassah
Hebrew University Medical Center in
Jerusalem, Israel. He continued,
"Once again, the large number of high-quality submissions to this
grant call attests to the sustained intense interest of
interventional oncologists worldwide to continue to advance our
field through robust scientific inquiry and clinical study. We're
proud that to date, SIO has been able to fund nine projects
representing a diverse set of outstanding investigators and
projects."
"As a leader in Interventional Oncology therapies, BTG is proud
to support this independent research fund in partnership with the
SIO," said Karen Skinner, BTG's Vice
President of Immuno-Oncology R&D. "We're thrilled by the
quality of these proposals and to see Interventional Radiologists
working alongside their colleagues in the Oncology community to
unlock the potential of combining these therapies. We believe this
collaborative approach is the best way to accelerate our
understanding of this field, and help expand the number of cancer
patients who might benefit from the immuno-oncology
revolution."
The Interventional Oncology/Immuno-Oncology research grant
program was established in 2017 to fund initiatives that evaluate
how interventional oncology therapies stimulate the immune system;
combine loco-regional and immunotherapy approaches to improve
clinical outcome; and improve the understanding of the underlying
mechanisms that cause different therapies to influence adaptive and
innate immunity, as well as underlying inflammation and
tumorigenesis.
Grant recipients were chosen by the SIO Interventional
Oncology/Immuno-Oncology Working Group, which includes both
interventional radiologists and immuno-oncologists.
About Society of Interventional Oncology (SIO)
SIO serves as the only membership-based organization dedicated
wholly to the emerging field of Interventional Oncology (IO),
working to establish, nurture, and support IO as the fourth pillar
of cancer therapy alongside medical, surgical, and radiation
oncology worldwide. IO therapies, such as embolization and tumor
ablation, combine the expertise of oncology and radiology and use
imaging technology to diagnose and treat localized cancers in ways
that are precisely targeted and minimally or non-invasive. The
society hosts the annual World Conference on Interventional
Oncology (WCIO). For more information, please visit:
www.sio-central.org
About BTG
BTG is a global healthcare company focused on Interventional
Medicine. Our innovative medical technology helps physicians treat
their patients through minimally invasive procedures. We have a
growing portfolio of products that advance the treatment of cancer,
vascular conditions and severe emphysema. To learn more about BTG
Interventional Medicine, please visit: btg-im.com.
For further information contact:
SIO
Amanda Winger O'Kane, Marketing
& Communications
+1-202-367-1164; aokane@sio-central.org
BTG plc
Chris Sampson, Corporate
Communications Director
+44-20-7575-1595; Mobile:
+44-7773-251-178